Evidence map›Paper›PMID 25349777›Full record

ArticleFEBS open bio2014

A novel peptide interferes with Mycobacterium tuberculosis virulence and survival.

Sachin Kumar Samuchiwal, Sultan Tousif, Dhiraj Kumar Singh, Arun Kumar, Anamika Ghosh, Kuhulika Bhalla, Prem Prakash, Sushil Kumar, Ashish Chandra Trivedi, Maitree Bhattacharyya and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. AntiTbPdb: a knowledgebase of anti-tubercular peptides.Database : the journal of biological databases and curation · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Sachin Kumar SamuchiwalRecombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, ICGEB, Aruna Asaf Ali Marg, New Delhi 110067, India.
Sultan TousifImmunology Group, International Centre for Genetic Engineering and Biotechnology, ICGEB, Aruna Asaf Ali Marg, New Delhi 110067, India ; Department of Biochemistry, University of Calcutta, 35, Ballygunge Circular Road, Kolkata 700 019, India ; School of Laboratory Medicine, College of Health Sciences, University of Kwazulu-Natal, Durban, South Africa.
Dhiraj Kumar SinghImmunology Group, International Centre for Genetic Engineering and Biotechnology, ICGEB, Aruna Asaf Ali Marg, New Delhi 110067, India.
Arun KumarImmunology Group, International Centre for Genetic Engineering and Biotechnology, ICGEB, Aruna Asaf Ali Marg, New Delhi 110067, India.
Anamika GhoshRecombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, ICGEB, Aruna Asaf Ali Marg, New Delhi 110067, India.
Kuhulika BhallaRecombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, ICGEB, Aruna Asaf Ali Marg, New Delhi 110067, India.
Prem PrakashRecombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, ICGEB, Aruna Asaf Ali Marg, New Delhi 110067, India.
Sushil KumarRecombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, ICGEB, Aruna Asaf Ali Marg, New Delhi 110067, India.
Ashish Chandra TrivediInnovative Life Discoveries Pvt. Ltd., IMT Manesar, Haryana, India.
Maitree BhattacharyyaDepartment of Biochemistry, University of Calcutta, 35, Ballygunge Circular Road, Kolkata 700 019, India.
Gobardhan DasSchool of Laboratory Medicine, College of Health Sciences, University of Kwazulu-Natal, Durban, South Africa.
Anand RanganathanRecombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, ICGEB, Aruna Asaf Ali Marg, New Delhi 110067, India.
International Centre for Genetic Engineering and Biotechnology · INUniversity of KwaZulu-Natal · ZAUniversity of Calcutta · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) is a huge global burden, with new and resistant strains emerging at an alarming rate, necessitating an urgent need for a new class of drug candidates. Here, we report that SL3, a novel 33-amino acid peptide, causes debilitating effects on mycobacterial morphology. Treatment with SL3 drastically inhibits the growth of Mycobacterium tuberculosis in vitro as well as in a pre-clinical mouse model for M.tb infection. Microarray analysis of SL3-expressing strain demonstrates wide-scale transcriptional disruption in M.tb. We therefore believe that SL3 and similar peptides may herald a new approach towards discovering new molecules for TB therapy.

Indexed as

AMADID, agilent microarray design identifiersAntimycobacterial peptidesCFU, colony forming unitsESAT6MOI, multiplicity of infectionMycobacterium tuberculosisProtein–protein interactionRD1, region of difference 1

Identifiers

PMID25349777
PMCPMC4208091
OpenAlexW2043546819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.